Remote Ischemic Conditioning in Patients With Acute Stroke: a Multicenter Randomized, Patient-assessor Blinded, Sham-controlled Study
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Stroke, Acute
- Sponsor
- Grethe Andersen
- Enrollment
- 1500
- Locations
- 4
- Primary Endpoint
- Modified Rankin Scale at 3 Months in Acute Stroke (AIS and ICH)
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
Our primary aim is to investigate whether remote ischemic conditioning (RIC) as an adjunctive treatment can improve long-term recovery in acute stroke patients as an adjunct to standard treatment.
Detailed Description
Stroke is the second-leading cause of death worldwide and a leading cause of serious, long-term disability. The most common type is acute ischemic stroke (AIS) which occurs in 85% of cases. Acute cerebral thromboembolism leads to an area of permanent damage (infarct core) in the most severely hypoperfused area and a surrounding area of impaired, yet salvageable tissue known as the "ischemic penumbra". Intravenous alteplase (IV tPA) and endovascular treatment (EVT) are approved acute reperfusion treatments of AIS to be started within the first 4½-6 hours (in some up to 24 hours) and as soon as possible after symptom onset to prevent the evolution of the infarct core. However, reperfusion itself may paradoxically result in tissue damage (reperfusion injury) and may contribute to infarct growth. Infarct progression can continue for days following a stroke, and failure of the collateral flow is a critical factor determining infarct growth. On the other hand, in intracerebral hemorrhage (ICH) the culprit is an eruption of blood into the brain parenchyma causing tissue destruction with a massive effect on adjacent brain tissues. Hematoma expansion as well as inflammatory pathways that are activated lead to further tissue damage, edema, and penumbral hypoperfusion. The prognosis after ICH is poor with a one-month mortality of 40%. Novel therapeutics and neuroprotective strategies that can be started ultra-early after symptom onset are urgently needed to reduce disability in both AIS and ICH. Ischemic conditioning is one of the most potent activators of endogenous protection against ischemia-reperfusion injury. Remote Ischemic Conditioning (RIC) can be applied as repeated short-lasting ischemia in a distant tissue that results in protection against subsequent long-lasting ischemic injury in the target organ. This protection can be applied prior to or during a prolonged ischemic event as remote ischemic pre-conditioning (RIPreC) and per-conditioning (RIPerC), respectively, or immediate after reperfusion as remote ischemic post-conditioning (RIPostC). RIC is commonly achieved by inflation of a blood pressure cuff to induce 5-minute cycles of limb ischemia alternating with 5 minutes of reperfusion. Preclinical studies show that RIC induces a promising infarct reduction in an experimental stroke model. Results from a recent proof-of-concept study at our institution indicate that RIPerC applied during ambulance transportation as an adjunctive to in-hospital IV tPA increases brain tissue survival after one month. Furthermore, RIPerC patients had less severe neurological symptoms at admission and tended to have decreased perfusion deficits. To-date, no serious adverse events have been documented in RIC. RIC is a non-pharmacologic and non-invasive treatment without noticeable discomfort that has first-aid potential worldwide. However, whether combined remote ischemic per- and postconditioning can improve long-term recovery in AIS and ICH has never been investigated in a randomized controlled trial.
Investigators
Grethe Andersen
Professor, DMSc, Senior Consultant, MD
Aarhus University Hospital
Eligibility Criteria
Inclusion Criteria
- •Male and female patients (≥ 18 years)
- •Prehospital putative stroke (Prehospital Stroke Score, PreSS \>= 1)
- •Onset of stroke symptoms \< 4 hours before RIC/Sham-RIC
- •Independent in daily living before symptom onset (mRS ≤ 2)
Exclusion Criteria
- •Intracranial aneurisms, intracranial arteriovenous malformation, cerebral neoplasm or abscess
- •Pregnancy
- •Severe peripheral arterial disease in the upper extremities
- •Concomitant acute life-threatening medical or surgical condition
- •Arteriovenous fistula in the arm selected for RIC
Outcomes
Primary Outcomes
Modified Rankin Scale at 3 Months in Acute Stroke (AIS and ICH)
Time Frame: 3 months
Clinical outcome (modified Rankin Scale) at 3 months in acute stroke patients (target diagnosis) (generalized ordinal logistic regression). The assessment will performed by two independent telephone or face-to-face assessors. the mRS range from 0 to 6, with higher scores representing worse outcome (mRS 0, no symptoms; mRS 6, death) If disagreement occurs the patient will be contacted by a third assessor (face-to-face or telephone) who is blinded to the intervention who will assess the level of dependency. * If disagreement occurs between two telephone assessments - a third, and final, telephone or face-to-face assessment will be made. * If disagreement occurs between one face-to-face assessment and one telephone assessment * the face-to-face will be considered the final assessment * If disagreement occurs between two face-to-face assessments - a third, and final, telephone or face-to-face assessment will be made.
Secondary Outcomes
- Difference Neurological Impairment During the First 24 Hours(24 hours)
- Clinical Outcome (Modified Rankin Scale (mRS) at 3 Months in Acute Ischemic Stroke(3 months)
- Clinical Outcome (Modified Rankin Scale (mRS) at 3 Months in Acute Ischemic Stroke Receiving Reperfusion Therapy(3 months)
- Clinical Outcome (Modified Rankin Scale (mRS) at 3 Months in Patients With Intracerebral Hemorrhage (ICH)(3 months)
- Difference in Proportion of Patients With Complete Remission of Symptoms Within 24 Hours (TIA; Both With and Without DWI)(3 months)
- Three-month and One-year Mortality(3 and 12 months)
- Quality of Life Measures at 3 Months in AIS and ICH Patients(3 months)
- Major Adverse Cardiac and Cerebral Events (MACCE)(3 months)
- Early Neurological Improvement in Acute Ischemic Stroke Patients (AIS)(24 hours)
- Early Neurological Improvement in Patients With Intracerebral Hemorrhage (ICH)(24 hours)
- Bed-day Use in AIS and ICH Patients(3 months)